Commentary: FMT safety alert ‘brought to light many questions’

The recent FDA warning due to the death of a patient following an investigational fecal microbiota transplant (FMT) brought to light many questions and concerns. The biggest question being, “In what situation did these deaths occur?” The report indicates that two immunocompromised patients received FMT and developed a multi-drug resistant infection and one of them died. We do not know if this FMT was done to help treat Clostridioides difficile (C. diff) infection, or for a different indication.
Large, phase 3 clinical trials for C. diff are currently excluding immunocompromised

Source link

Related posts

Biosimilars Poised to Move Needle in GI, but Hurdles Remain


DAAs Best for Cutting CVD Risk in HCV


How Effective Are Manufacturer Recommendations for Cleaning Duodenoscopes?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy